These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 10428907)

  • 1. Construction and characterization of mutants of the TEM-1 beta-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to beta-lactamase inhibitors.
    Stapleton PD; Shannon KP; French GL
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1881-7. PubMed ID: 10428907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
    Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS
    J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection and characterization of beta-lactam-beta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase gene.
    Vakulenko SB; Geryk B; Kotra LP; Mobashery S; Lerner SA
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1542-8. PubMed ID: 9660980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino acid substitutions at Ambler position Gly238 in the SHV-1 beta-lactamase: exploring sequence requirements for resistance to penicillins and cephalosporins.
    Hujer AM; Hujer KM; Helfand MS; Anderson VE; Bonomo RA
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3971-7. PubMed ID: 12435703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemophilus influenzae bla(ROB-1) mutations in hypermutagenic deltaampC Escherichia coli conferring resistance to cefotaxime and beta-lactamase inhibitors and increased susceptibility to cefaclor.
    Galán JC; Morosini MI; Baquero MR; Reig M; Baquero F
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2551-7. PubMed ID: 12878518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic study of resistance of beta-lactamase-inhibitor-resistant TEM enzymes which differ by naturally occurring variations and by site-directed substitution at Asp276.
    Caniça MM; Caroff N; Barthélémy M; Labia R; Krishnamoorthy R; Paul G; Dupret JM
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1323-8. PubMed ID: 9624468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amino acid substitutions causing inhibitor resistance in TEM beta-lactamases compromise the extended-spectrum phenotype in SHV extended-spectrum beta-lactamases.
    Randegger CC; Hächler H
    J Antimicrob Chemother; 2001 May; 47(5):547-54. PubMed ID: 11328764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substitution of Met-69 by Ala or Gly in TEM-1 beta-lactamase confer an increased susceptibility to clavulanic acid and other inhibitors.
    Madec S; Blin C; Krishnamoorthy R; Picard B; Chaibi el B; Fouchereau-Péron M; Labia R
    FEMS Microbiol Lett; 2002 May; 211(1):13-6. PubMed ID: 12052544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A complex mutant of TEM-1 beta-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate.
    Sirot D; Recule C; Chaibi EB; Bret L; Croize J; Chanal-Claris C; Labia R; Sirot J
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1322-5. PubMed ID: 9174192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant TEM beta-lactamase producing resistance to ceftazidime, ampicillins, and beta-lactamase inhibitors.
    Vakulenko S; Golemi D
    Antimicrob Agents Chemother; 2002 Mar; 46(3):646-53. PubMed ID: 11850243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 beta-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid.
    Swarén P; Golemi D; Cabantous S; Bulychev A; Maveyraud L; Mobashery S; Samama JP
    Biochemistry; 1999 Jul; 38(30):9570-6. PubMed ID: 10423234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effects of functionally distinct substitutions in β-lactamase variants shed light on the evolution of bacterial drug resistance.
    Patel MP; Hu L; Brown CA; Sun Z; Adamski CJ; Stojanoski V; Sankaran B; Prasad BVV; Palzkill T
    J Biol Chem; 2018 Nov; 293(46):17971-17984. PubMed ID: 30275013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of clavulanate resistance conferred by a Ser-244 mutant of TEM-1 beta-lactamase as a result of a second mutation (Arg to Ser at position 164) that enhances activity against ceftazidime.
    Imtiaz U; Manavathu EK; Mobashery S; Lerner SA
    Antimicrob Agents Chemother; 1994 May; 38(5):1134-9. PubMed ID: 8067751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and characterization of an OHIO-1 beta-lactamase bearing Met69Ile and Gly238Ser mutations.
    Bonomo RA; Knox JR; Rudin SD; Shlaes DM
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1940-3. PubMed ID: 9303389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme.
    Lin S; Thomas M; Shlaes DM; Rudin SD; Knox JR; Anderson V; Bonomo RA
    Biochem J; 1998 Jul; 333 ( Pt 2)(Pt 2):395-400. PubMed ID: 9735103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy.
    Rice LB; Carias LL; Bonomo RA; Shlaes DM
    J Infect Dis; 1996 Jan; 173(1):151-8. PubMed ID: 8537652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new TEM-derived extended-spectrum beta-lactamase (TEM-91) with an R164C substitution at the omega-loop confers ceftazidime resistance.
    Kurokawa H; Shibata N; Doi Y; Shibayama K; Kamachi K; Yagi T; Arakawa Y
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2981-3. PubMed ID: 12937007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and amino acid sequence of IRT-4, a novel TEM-type enzyme with a decreased susceptibility to beta-lactamase inhibitors.
    Brun T; Péduzzi J; Caniça MM; Paul G; Névot P; Barthélémy M; Labia R
    FEMS Microbiol Lett; 1994 Jul; 120(1-2):111-7. PubMed ID: 8056282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.
    Drawz SM; Bethel CR; Hujer KM; Hurless KN; Distler AM; Caselli E; Prati F; Bonomo RA
    Biochemistry; 2009 Jun; 48(21):4557-66. PubMed ID: 19351161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TEM-109 (CMT-5), a natural complex mutant of TEM-1 beta-lactamase combining the amino acid substitutions of TEM-6 and TEM-33 (IRT-5).
    Robin F; Delmas J; Chanal C; Sirot D; Sirot J; Bonnet R
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4443-7. PubMed ID: 16251281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.